How Niaspan Lowers Cholesterol
Niaspan, the extended-release form of niacin (vitamin B3), primarily reduces LDL cholesterol by 5-25% and triglycerides by 20-50%, while raising HDL cholesterol by 15-35%.[1] It works by inhibiting hepatic synthesis of very low-density lipoprotein (VLDL), the precursor to LDL. Less VLDL production means fewer LDL particles form and circulate.
Mechanism Targeting Liver Fat Production
In the liver, niacin blocks the enzyme diacylglycerol acyltransferase-2 (DGAT2), which limits fat assembly into VLDL particles for export. This reduces VLDL secretion, lowering triglycerides and shifting lipid metabolism away from atherogenic LDL.[1][2] Niaspan's slow release sustains this effect over 24 hours, minimizing peak-dose side effects like flushing.
Boosting HDL Levels
Niaspan increases HDL by decreasing endothelial lipase activity, an enzyme that breaks down HDL. Higher HDL promotes reverse cholesterol transport, moving cholesterol from arteries back to the liver for excretion.[2]
Effects on Other Lipids
It cuts lipoprotein(a) [Lp(a)] by up to 30%, a genetically driven risk factor for heart disease not targeted by statins.[1] Triglyceride reduction happens via enhanced clearance of VLDL remnants through lipoprotein lipase activation.
How It Compares to Statins
Unlike statins, which block HMG-CoA reductase to cut LDL synthesis, Niaspan acts downstream on VLDL packaging and has unique HDL/Lp(a) benefits. Doctors often combine them for broader control, as in the AIM-HIGH trial, where Niaspan added modest CVD risk reduction atop simvastatin.[3]
Common Side Effects Patients Report
Flushing (warmth, redness) hits 80% initially due to prostaglandin release but fades with tolerance or aspirin pretreatment. Liver enzyme elevation or hyperglycemia can occur; monitoring is standard.[1]
[1]: Niaspan Prescribing Information (AbbVie)
[2]: DrugPatentWatch.com - Niaspan Mechanism
[3]: AIM-HIGH Investigators. N Engl J Med. 2011;365:2255-2267.